[{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Yunfeng Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Bevacizumab","moa":"VEGF-A receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Etana Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etana Biotechnologies \/ Yunfeng Capital","highestDevelopmentStatusID":"15","companyTruncated":"Etana Biotechnologies \/ Yunfeng Capital"}]

Find Clinical Drug Pipeline Developments & Deals by Etana Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The financing will be used for further strengthening the company’s pipeline and portfolio especially in Oncology area. Etana will produce Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for cancer patients i...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 20, 2023

                          Lead Product(s) : Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Yunfeng Capital

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank